Critical assessment of combination therapy development

Area of Science:

• Cardiovascular pharmacology
• Clinical pharmacy
• Internal medicine

Background:

• Suboptimal blood pressure control affects many hypertensive patients, with less than 40% reaching treatment targets.
• Improved patient compliance is crucial for effective hypertension management.
• Fixed-dose combinations offer a strategy to enhance adherence and therapeutic outcomes.

Purpose of the Study:

• To evaluate the development and efficacy of fixed-dose combination antihypertensive medications.
• To explore the benefits of combining agents with complementary mechanisms of action.
• To assess the 24-hour efficacy and safety of a fixed-dose combination tablet.

Main Methods:

• Development of a fixed-dose combination tablet (felodipine and metoprolol) utilizing extended-release technology.
• Pharmacokinetic and drug interaction studies.
• Clinical trials including crossover and parallel-group designs to assess 24-hour efficacy and safety.

Main Results:

• The fixed-dose combination formulation demonstrated sustained blood pressure control over a 24-hour period.
• Pharmacokinetic and clinical evaluations established the efficacy and safety profile of the combination.
• The combination therapy showed potential for improved patient compliance due to a single-pill regimen.

Conclusions:

• Fixed-dose combination therapy is a viable strategy to improve blood pressure control in hypertensive patients.
• Combining antihypertensive agents with complementary actions can enhance efficacy and tolerability.
• The felodipine and metoprolol fixed-dose combination offers an effective and safe treatment option for hypertension management.